Bank Of New York Mellon Corp Nurix Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $1.58 Million - $2.34 Million	160,544 New	160,544 $1.76 Million
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $284,292 - $456,759	23,057 Added 16.99%	158,760 $2.07 Million
Q2 2022 Aug 15, 2022	BUY	$7.88 - $14.82 $248,858 - $468,030	31,581 Added 30.33%	135,703 $1.72 Million
Q1 2022 May 11, 2022	BUY	$12.94 - $29.65 $1,345 - $3,083	104 Added 0.1%	104,122 $1.46 Million
Q4 2021 Feb 11, 2022	BUY	$26.43 - $34.5 $151,470 - $197,719	5,731 Added 5.83%	104,018 $3.01 Million
Q3 2021 Nov 12, 2021	BUY	$22.71 - $36.69 $460,104 - $743,339	20,260 Added 25.97%	98,287 $2.95 Million
Q2 2021 Aug 11, 2021	BUY	$24.21 - $35.89 $274,275 - $406,597	11,329 Added 16.99%	78,027 $2.07 Million
Q1 2021 May 13, 2021	BUY	$26.98 - $50.17 $602,301 - $1.12 Million	22,324 Added 50.31%	66,698 $2.07 Million
Q4 2020 Feb 09, 2021	BUY	$22.85 - $48.44 $376,613 - $798,388	16,482 Added 59.09%	44,374 $1.46 Million
Q3 2020 Nov 12, 2020	BUY	$16.05 - $34.91 $447,666 - $973,709	27,892 New	27,892 $973,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.